Correction to: Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology (Annals of Oncology (2011) 22(5) (1019–1029), (S0923753419385072), (10.1093/annonc/mdq442));Management of sepsis in neutropenic patients: Guidelines from the infectious diseases working party of the German Society of Hematology and Oncology

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1019-1029

  Penack, O ^a   Buchheidt, D ^b   Christopeit, M ^c   von Lilienfeld Toal, M ^d   Massenkeil, G ^e   Hentrich, M ^f   Salwender, H ^g   Wolf, H H ^c   Ostermann, H ^h  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e Municipal Hospital Gütersloh   (Germany)

^f Harlaching Hospital   (Germany)

^g ASKLEPIOS KLINIK ALTONA   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

Author keywords

Guideline; Management; Neutropenia; Sepsis

Indexed keywords

AMINOGLYCOSIDE; ANTIFUNGAL AGENT; ANTITHROMBIN III; CARBAPENEM; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; DOBUTAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; HUMAN ALBUMIN; HYPERTENSIVE FACTOR; IMMUNOGLOBULIN; INFUSION FLUID; MEROPENEM; NORADRENALIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN C; VASOPRESSIN;

ACUTE KIDNEY FAILURE; ANTIMICROBIAL THERAPY; BLOOD CULTURE; CANCER MORTALITY; CANCER PATIENT; DIAGNOSTIC TEST; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; ERYTHROCYTE CONCENTRATE; GERMANY; GRANULOCYTE TRANSFUSION; HUMAN; HYPOTENSION; LOW DRUG DOSE; LUNG INSUFFICIENCY; MEDICAL SOCIETY; NEPHROTOXICITY; NEUTROPENIA; NUTRITION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SEPSIS; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

EID: 79955496107     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr337     Document Type: Erratum

References (125)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
2. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103-1110.
3. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32: 851-854.
4. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17-60.
5. Green RS, Djogovic D, Gray S et al. Canadian Association of Emergency Physicians Sepsis Guidelines: the optimal management of severe sepsis in Canadian emergency departments. CJEM 2008; 10: 443-459.
6. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145: 24-33.
7. Pottecher T, Calvat S, Dupont H et al. Haemodynamic management of severe sepsis: recommendations of the French Intensive Care Societies (SFAR/SRLF) Consensus Conference, 13 October 2005, Paris, France. Crit Care 2006; 10: 311.
8. Guidelines for the management of severe sepsis and septic shock. The International Sepsis Forum. Intensive Care Med 2001; 27 (Suppl 1): S1-S134.
9. Marik PE, Pastores SM, Annane D et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36: 1937-1949.
10. Riewald M, Petrovan RJ, Donner A et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-1882.
11. Aird WC. Endothelium as a therapeutic target in sepsis. Curr Drug Targets 2007; 8: 501-507.
12. den Uil CA, Klijn E, Lagrand WK et al. The microcirculation in health and critical disease. Prog Cardiovasc Dis 2008; 51: 161-170.
13. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
14. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256.
15. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-538.
16. Danai PA, Moss M, Mannino DM, Martin GS. The epidemiology of sepsis in patients with malignancy. Chest 2006; 129: 1432-1440.
17. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.
18. Moerer O, Quintel M. [Sepsis in adult patients-definitions, epidemiology and economic aspects]. Internist (Berl) 2009; 50: 788, 790-784, 796-788.
19. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-259.
20. Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051.
21. Uys A, Rapoport BL, Fickl H et al. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care 2007; 16: 475-483.
22. Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-353.
23. Sculier JP, Paesmans M, Markiewicz E, Berghmans T. Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit. Crit Care Med 2000; 28: 2786-2792.
24. Cherif H, Martling CR, Hansen J et al. Predictors of short and long-term outcome in patients with hematological disorders admitted to the intensive care unit for a life-threatening complication. Support Care Cancer 2007; 15: 1393-1398.
25. Vandijck DM, Benoit DD, Depuydt PO et al. Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies. Intensive Care Med 2008; 34: 847-855.
26. Nishida K, Palalay MP. Prognostic factors and utility of scoring systems in patients with hematological malignancies admitted to the intensive care unit and required a mechanical ventilator. Hawaii Med J 2008; 67: 264-269.
27. Ostermann H, Kratz-Albers K, Mesters RM et al. Reciprocal changes in circulating interleukin-6 and its soluble receptor during evolving sepsis in leukocytopenic patients. J Infect Dis 1997; 176: 825-828.
28. Sakr Y, Sponholz C, Tuche F et al. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008; 36: 396-407.
29. von Lilienfeld-Toal M, Schneider A, Orlopp K et al. Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies. Support Care Cancer 2006; 14: 1241-1245.
30. Mesters RM, Mannucci PM, Coppola R et al. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996; 88: 881-886.
31. Link H, Bohme A, Cornely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82 (Suppl 2): S105-S117.
32. Buchheidt D, Bohme A, Cornely OA et al. Diagnosis and treatment of documented infections in neutropenic patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 (Suppl 2): S127-S132.
33. Ruhnke M, Bohme A, Buchheidt D et al. Diagnosis of invasive fungal infections in hematology and oncology-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 (Suppl 2): S141-S148.
34. Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents 2008; 32 (Suppl 1): S30-S33.
35. Penack O, Rempf P, Eisenblatter M et al. Bloodstream infections in neutropenic patients: early detection of pathogens and directed antimicrobial therapy due to surveillance blood cultures. Ann Oncol 2007; 18: 1870-1874.
36. Mancini N, Clerici D, Diotti R et al. Molecular diagnosis of sepsis in neutropenic patients with haematological malignancies. J Med Microbiol 2008; 57: 601-604.
37. Ammann RA, Zucol F, Aebi C et al. Real-time broad-range PCR versus blood culture. A prospective pilot study in pediatric cancer patients with fever and neutropenia. Support Care Cancer 2007; 15: 637-641.
38. von Lilienfeld-Toal M, Lehmann LE, Raadts AD et al. Utility of a commercially available multiplex real-time PCR assay to detect bacterial and fungal pathogens in febrile neutropenia. J Clin Microbiol 2009; 47: 2405-2410.
39. Persson L, Dahl H, Linde A et al. Human cytomegalovirus, human herpesvirus-6 and human herpesvirus-7 in neutropenic patients with fever of unknown origin. Clin Microbiol Infect 2003; 9: 640-644.
40. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596.
41. Maschmeyer G, Beinert T, Buchheidt D et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 2009; 45: 2462-2472.
42. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003; 326: 1111.
43. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328: 668.
44. Bohme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
45. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
46. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377.
47. Choi PT, Yip G, Quinonez LG, Cook DJ. Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 1999; 27: 200-210.
48. Alderson P, Bunn F, Lefebvre C et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2004; 4: CD001208.
49. Sharma VK, Dellinger RP. The International Sepsis Forum's controversies in sepsis: my initial vasopressor agent in septic shock is norepinephrine rather than dopamine. Crit Care 2003; 7: 3-5.
50. Fukuoka T, Nishimura M, Imanaka H et al. Effects of norepinephrine on renal function in septic patients with normal and elevated serum lactate levels. Crit Care Med 1989; 17: 1104-1107.
51. Bourgoin A, Leone M, Delmas A et al. Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Crit Care Med 2005; 33: 780-786.
52. Obritsch MD, Jung R, Fish DN, MacLaren R. Effects of continuous vasopressin infusion in patients with septic shock. Ann Pharmacother 2004; 38: 1117-1122.
53. Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47: 699-703; discussion 703-695.
54. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96: 576-582.
55. Russell JA, Walley KR, Singer J et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358: 877-887.
56. Vincent JL, Van der Linden P, Domb M et al. Dopamine compared with dobutamine in experimental septic shock: relevance to fluid administration. Anesth Analg 1987; 66: 565-571.
57. Azoulay E, Schlemmer B. Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Med 2006; 32: 808-822.
58. Sevransky JE, Levy MM, Marini JJ. Mechanical ventilation in sepsis-induced acute lung injury/acute respiratory distress syndrome: an evidence-based review. Crit Care Med 2004; 32: S548-S553.
59. Conti G, Marino P, Cogliati A et al. Noninvasive ventilation for the treatment of acute respiratory failure in patients with hematologic malignancies: a pilot study. Intensive Care Med 1998; 24: 1283-1288.
60. Hilbert G, Gruson D, Vargas F et al. Noninvasive continuous positive airway pressure in neutropenic patients with acute respiratory failure requiring intensive care unit admission. Crit Care Med 2000; 28: 3185-3190.
61. Hilbert G, Gruson D, Vargas F et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med 2001; 344: 481-487.
62. Horn DL, Morrison DC, Opal SM et al. What are the microbial components implicated in the pathogenesis of sepsis? Report on a symposium. Clin Infect Dis 2000; 31: 851-858.
63. Azoulay E, Thiery G, Chevret S et al. The prognosis of acute respiratory failure in critically ill cancer patients. Medicine (Baltimore) 2004; 83: 360-370.
64. Adda M, Coquet I, Darmon M et al. Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure. Crit Care Med 2008; 36: 2766-2772.
65. Hummel M, Rudert S, Hof H et al. Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates. Ann Hematol 2008; 87: 291-297.
66. Rabbat A, Chaoui D, Lefebvre A et al. Is BAL useful in patients with acute myeloid leukemia admitted in ICU for severe respiratory complications? Leukemia 2008; 22: 1361-1367.
67. Azoulay E, Mokart D, Rabbat A et al. Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: prospective multicenter data. Crit Care Med 2008; 36: 100-107.
68. Karlin L, Darmon M, Thiery G et al. Respiratory status deterioration during GCSF-induced neutropenia recovery. Bone Marrow Transplant 2005; 36: 245-250.
69. Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 351: 159-169.
70. Wan L, Bagshaw SM, Langenberg C et al. Pathophysiology of septic acute kidney injury: what do we really know? Crit Care Med 2008; 36: S198-S203.
71. John S, Eckardt KU. Renal replacement strategies in the ICU. Chest 2007; 132: 1379-1388.
72. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG et al. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med 2002; 30: 2205-2211.
73. Kellum JA, Angus DC, Johnson JP et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med 2002; 28: 29-37.
74. Tonelli M, Manns B, Feller-Kopman D. Acute renal failure in the intensive care unit: a systematic review of the impact of dialytic modality on mortality and renal recovery. Am J Kidney Dis 2002; 40: 875-885.
75. Ghahramani N, Shadrou S, Hollenbeak C. A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure. Nephrology (Carlton) 2008; 13: 570-578.
76. Gasparovic V, Filipovic-Grcic I, Merkler M, Pisl Z. Continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD)-what is the procedure of choice in critically ill patients? Ren Fail 2003; 25: 855-862.
77. Lins RL, Elseviers MM, Van der Niepen P et al. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial. Nephrol Dial Transplant 2009; 24: 512-518.
78. Ricci Z, Ronco C. Dose and efficiency of renal replacement therapy: continuous renal replacement therapy versus intermittent hemodialysis versus slow extended daily dialysis. Crit Care Med 2008; 36: S229-S237.
79. Palevsky PM, Zhang JH, O'Connor TZ et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359: 7-20.
80. Bellomo R, Chapman M, Finfer S et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 2139-2143.
81. Kellum JA, Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001; 29: 1526-1531.
82. Krishnan JA, Parce PB, Martinez A et al. Caloric intake in medical ICU patients: consistency of care with guidelines and relationship to clinical outcomes. Chest 2003; 124: 297-305.
83. Kreymann KG, Berger MM, Deutz NE et al. ESPEN Guidelines on Enteral Nutrition: intensive care. Clin Nutr 2006; 25: 210-223.
84. Singer P, Berger MM, Van den Berghe G et al. ESPEN Guidelines on Parenteral Nutrition: intensive care. Clin Nutr 2009; 28: 387-400.
85. Galban C, Montejo JC, Mesejo A et al. An immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients. Crit Care Med 2000; 28: 643-648.
86. Kosiborod M, Inzucchi SE, Krumholz HM et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomesbased measure of risk. Circulation 2008; 117: 1018-1027.
87. Bagshaw SM, Egi M, George C, Bellomo R. Early blood glucose control and mortality in critically ill patients in Australia. Crit Care Med 2009; 37: 463-470.
88. Griesdale DE, de Souza RJ, van Dam RM et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009; 180: 821-827.
89. Brunkhorst FM, Engel C, Bloos F et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-139.
90. Finfer S, Chittock DR, Su SY et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297.
91. Van den Berghe G, Wilmer A, Hermans G et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449-461.
92. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367.
93. Annane D, Cariou A, Maxime V. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010; 303: 341-348.
94. Angstwurm MW, Engelmann L, Zimmermann T et al. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiplecenter study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 2007; 35: 118-126.
95. Minneci PC, Deans KJ, Banks SM et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004; 141: 47-56.
96. Cronin L, Cook DJ, Carlet J et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430-1439.
97. Keh D, Boehnke T, Weber-Cartens S et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003; 167: 512-520.
98. Kaufmann I, Briegel J, Schliephake F et al. Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions. Intensive Care Med 2008; 34: 344-349.
99. Sprung CL, Annane D, Keh D et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-124.
100. Bollaert PE, Charpentier C, Levy B et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645-650.
101. Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-871.
102. Annane D, Bellissant E, Bollaert PE et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301: 2362-2375.
103. Sligl WI, Milner DA Jr, Sundar S et al. Safety and efficacy of corticosteroids for the treatment of septic shock: A systematic review and meta-analysis. Clin Infect Dis 2009; 49: 93-101.
104. Jaimes F, De La Rosa G, Morales C et al. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 2009; 37: 1185-1196.
105. Warren BL, Eid A, Singer P et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-1878.
106. Afshari A, Wetterslev J, Brok J, Moller AM. Antithrombin III for critically ill patients. Cochrane Database Syst Rev 2008; 3: CD005370.
107. Hoffmann JN, Wiedermann CJ, Juers M et al. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006; 95: 850-856.
108. Kienast J, Juers M, Wiedermann CJ et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4: 90-97.
109. Wiedermann CJ, Hoffmann JN, Juers M et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34: 285-292.
110. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
111. Abraham E, Laterre PF, Garg R et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-1341.
112. Levy M, Levi M, Williams MD et al. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis. Intensive Care Med 2009; 35: 1196-1203.
113. Levi M, Levy M, Williams MD et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007; 176: 483-490.
114. Fisher CJ Jr, Dhainaut JF, Opal SM et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-1843.
115. Fisher CJ Jr., Slotman GJ, Opal SM et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22: 12-21.
116. Opal SM, Fisher CJ Jr, Dhainaut JF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebocontrolled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115-1124.
117. Clark OA, Lyman GH, Castro AA et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005; 23: 4198-4214.
118. Azoulay E, Darmon M, Delclaux C et al. Deterioration of previous acute lung injury during neutropenia recovery. Crit Care Med 2002; 30: 781-786.
119. Root RK, Lodato RF, Patrick W et al. Multicenter, double-blind, placebocontrolled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31: 367-373.
120. Wunderink R, Leeper K Jr, Schein R et al. Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 2001; 119: 523-529.
121. Hentrich M, Fehnle K, Ostermann H et al. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 2006; 34: 1319-1325.
122. Turgeon AF, Hutton B, Fergusson DA et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007; 146: 193-203.
123. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007; 35(12): 2686-2692.
124. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007; 35(12): 2677-2685.
125. Seidel MG, Peters C, Wacker A et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant 2008; 42: 679-684.